{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-100010","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.212442+00:00","generated_at":"2026-05-31T04:49:26.474294+00:00","sec_items":["2.03","8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theriva Biologics awarded €2.28M Spanish government funding for THERICEL cell platform","bullets":["€1.33M unsecured loan lump sum in Q4 2024; interest 4.015%; repayable over 7 yrs after 3-yr grace.","€0.95M grant to Universitat Autònoma de Barcelona paid in annual installments over 3 years.","Funds to advance suspension cell platform for adenovirus/AAV therapies; scaling VCN-01 production.","Award validates proprietary A549 suspension cell platform for clinical manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-100010","json":"https://secwatch.observer/filing/0001104659-24-100010.json","markdown":"https://secwatch.observer/filing/0001104659-24-100010.md","text":"https://secwatch.observer/filing/0001104659-24-100010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924100010/0001104659-24-100010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924100010/tm2424064d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:49:26.474294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}